Therefore,we found that JNK inhibition at low cisplatin concentrationsis highly effective at killing non-small-cell lung cancer A549 cells.Since both A549 and DLD-1 cell lines harbor activating KRAS mutations (Cellosaurus.org, 2023), we hypothesize that the differencein JNK functions at different concentrations of cisplatin may be dueto increased KRAS activity. Here, KRAS is linked to non-small cell lung carcinoma.